Logo image of LFCR

LIFECORE BIOMEDICAL INC (LFCR) Stock Price, Quote, News and Overview

NASDAQ:LFCR - Nasdaq - US5147661046 - Common Stock - Currency: USD

5.94  +0.22 (+3.85%)

After market: 5.94 0 (0%)

LFCR Quote, Performance and Key Statistics

LIFECORE BIOMEDICAL INC

NASDAQ:LFCR (2/4/2025, 8:00:02 PM)

After market: 5.94 0 (0%)

5.94

+0.22 (+3.85%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High8.59
52 Week Low3.68
Market Cap218.77M
Shares36.83M
Float34.82M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO02-15 1996-02-15


LFCR short term performance overview.The bars show the price performance of LFCR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

LFCR long term performance overview.The bars show the price performance of LFCR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30

The current stock price of LFCR is 5.94 USD. In the past month the price decreased by -22.05%. In the past year, price decreased by -30.53%.

LIFECORE BIOMEDICAL INC / LFCR Daily stock chart

LFCR Latest News, Press Releases and Analysis

News Image
2 days ago - Lifecore Biomedical, Inc.

Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and...

News Image
18 days ago - Lifecore Biomedical, Inc.

Lifecore Biomedical Announces Special Stockholder Meeting

Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms

News Image
18 days ago - Lifecore Biomedical, Inc.

Lifecore Biomedical Announces Special Stockholder Meeting

Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series...

News Image
a month ago - Lifecore Biomedical, Inc.

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue ...

LFCR Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 26.56 222.07B
DHR DANAHER CORP 28.71 155.30B
A AGILENT TECHNOLOGIES INC 27.8 41.93B
IQV IQVIA HOLDINGS INC 18.42 36.31B
MTD METTLER-TOLEDO INTERNATIONAL 35.12 28.27B
WAT WATERS CORP 36.03 24.37B
WST WEST PHARMACEUTICAL SERVICES 48.97 23.97B
ILMN ILLUMINA INC 71.79 19.70B
ICLR ICON PLC 13.78 15.96B
RVTY REVVITY INC 25.13 14.99B
AVTR AVANTOR INC 22.46 14.98B
TECH BIO-TECHNE CORP 40.53 11.53B

About LFCR

Company Profile

LFCR logo image Lifecore Biomedical, Inc. is a contract development and manufacturing organization, which engages in the provision of differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is headquartered in Chaska, Minnesota and currently employs 524 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Company Info

LIFECORE BIOMEDICAL INC

3515 Lyman Boulevard

Chaska MINNESOTA US

Employees: 524

Company Website: https://www.lifecore.com/

Investor Relations: https://ir.lifecore.com/

Phone: 19523684300

LFCR FAQ

What is the stock price of LFCR?

The current stock price of LFCR is 5.94 USD.


What is the symbol for LIFECORE BIOMEDICAL INC stock?

The exchange symbol of LIFECORE BIOMEDICAL INC is LFCR and it is listed on the Nasdaq exchange.


On which exchange is LFCR stock listed?

LFCR stock is listed on the Nasdaq exchange.


Is LFCR a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for LFCR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of LFCR.


Does LFCR stock pay dividends?

LFCR does not pay a dividend.


What is the Price/Earnings (PE) ratio of LFCR?

LFCR does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).


What is the Short Interest ratio of LFCR stock?

The outstanding short interest for LFCR is 7.45% of its float.


LFCR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LFCR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LFCR. Both the profitability and financial health of LFCR have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LFCR Financial Highlights

Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS decreased by 75.86% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.42%
ROE -27.42%
Debt/Equity 1.99
Chartmill High Growth Momentum
EPS Q2Q%-164.77%
Sales Q2Q%8.01%
EPS 1Y (TTM)75.86%
Revenue 1Y (TTM)21.4%

LFCR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to LFCR. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -304.88% and a revenue growth 2.52% for LFCR


Ownership
Inst Owners61.64%
Ins Owners1.53%
Short Float %7.45%
Short Ratio9.76
Analysts
Analysts77.78
Price Target8.67 (45.96%)
EPS Next Y-304.88%
Revenue Next Year2.52%